Magnitude and timing of the antiviral response determine SARS-CoV-2 replication early in infection

Nagarjuna R. Cheemarla[1], Timothy A. Watkins[1,2], Valia T. Mihaylova[1], Bao Wang[1,2], Dejian Zhao[3,4], Guilin Wang[3,4], Marie L. Landry[1,5], and Ellen F. Foxman[1,2*]

[1]Department of Laboratory Medicine, [2]Department of Immunobiology, [3]Department of Genetics, [4]Yale Center for Genomic Analysis, and [5]Department of Internal Medicine, Yale School of Medicine, New Haven CT, U.S.A. 06520

*Corresponding author
Correspondence: ellen.foxman@yale.edu

Abstract

The interferon response is a potent antiviral defense mechanism, but its effectiveness depends on its timing relative to viral replication. Here, we report viral replication and host response kinetics in patients at the start of SARS-CoV-2 infection and explore the impact of these kinetics experimentally. In both longitudinal patient nasopharyngeal samples and airway epithelial organoids, we found that SARS-CoV-2 initially replicated exponentially with a doubling time of ~6hr, and induced interferon stimulated genes (ISGs) with delayed timing relative to viral replication. Prior exposure to rhinovirus increased ISG levels and blocked SARS-CoV-2 replication. Conversely, inhibiting ISG induction abrogated interference by rhinovirus and enhanced SARS-CoV-2 replication rate. These results demonstrate the importance of initial interferon-mediated defenses in determining the extent to which SARS-CoV-2 can replicate at the start of infection and indicate that biological variables that alter the airway interferon response, including heterologous induction of innate immunity by other viruses, could profoundly impact SARS-CoV-2 susceptibility and transmission.

Introduction

The novel coronavirus SARS-CoV-2 emerged in late 2019 and has led to a global pandemic, causing

over 98M infections and 2.1M deaths at the time of this writing (Dong, 2020). This huge impact has

motivated efforts to understand the host immune response to this virus, both to better predict patient

outcomes and to design interventions. For an emerging viral infection such as SARS-CoV-2, innate

immune responses can be particularly important in host protection, as these responses do not require

prior exposure to effectively defend against a pathogen. Studies based on patient samples indicate that

dysregulation of innate immune responses late in infection drives immunopathology in severe COVID-

19 (Galani et al., 2021; Lee and Shin, 2020; Lucas et al., 2020), but there are relatively few reports

describing host responses to SARS-CoV-2 in patients at the start of infection, when innate immune

mechanisms are most likely to contribute to host defense.

SARS-CoV-2 enters the body and first replicates in the upper respiratory tract, achieving the highest

viral load in the first few days following infection (Wolfel et al., 2020; Zou et al., 2020). High viral load in

the nasopharynx correlates strongly with transmissibility in contact tracing studies, and significant viral

replication following exposure is likely a prerequisite, although certainly not the only factor, for COVID-

19 disease progression (Cevik, 2020; He et al., 2020). A likely candidate for controlling the infection at

the earliest stages is the mucosal interferon response. This defense mechanism is initiated when

pattern recognition receptors within epithelial cells and immune cells sense general features shared by

many viruses, such as common structural features of viral RNA. This recognition event triggers

expression of type I and type III interferons (IFNs) and interferon-stimulated genes (ISGs). Secreted

interferons, in turn, bind to cell surface receptors on nearby cells, amplifying ISG expression and

creating an antiviral state in the mucosal barrier. Many ISGs encode effectors which directly block viral

replication within virus target cells, whereas others encode cytokines which recruit and activate cells of

the immune system (Odendall and Kagan, 2015; Schneider et al., 2014).

Recent evidence supports a protective role for the interferon response in COVID-19, although there is

also evidence that the virus antagonizes this response. Recombinant interferon blocks SARS-CoV-2

replication in vitro, and genetic deficiencies in the Type I interferon response as well as anti-interferon

autoantibodies have been linked to greater COVID-19 disease severity (Bastard et al., 2020;

Lokugamage et al., 2020; Pairo-Castineira et al., 2020; Vanderheiden et al., 2020; Zhang et al., 2020).

Furthermore, early data from trials of recombinant Type I or Type III interferon for COVID-19 indicate a

therapeutic benefit, particularly when patients are treated early in disease(Feld, 2020; Monk, 2020;

Wang, 2020).   However, during initial infection of the upper respiratory tract, the kinetics of ISG

induction by SARS-CoV-2 are not clear. ISG expression in SARS-CoV-2 infected epithelia can be

observed in vitro and in patients, but there is also strong evidence that SARS-CoV-2 antagonizes the

interferon response, which likely affects the magnitude and timing of this response (Banerjee et al.,

2020; Blanco-Melo et al., 2020; Konno et al., 2020; Martin-Sancho et al., 2020; Ravindra et al., 2020;

Xia et al., 2020; Zhou et al., 2020). Since a major beneficial function of ISGs is preventing viral

replication, the kinetics of the interferon response early in infection are likely to determine its protective

impact, and host and environmental factors which modulate the timing of this response may be key

determinants of whether the virus can amplify to a high viral load following infection.

One factor that can potentially modulate antiviral defenses in the airway epithelium is induction of the

ISGs by other viruses, and such effects may be particularly important in limiting viruses which

successfully block autologous interferon induction. Rhinovirus, the most frequent cause of the common

cold, is frequently detected in the human upper respiratory tract in the presence and absence of

symptoms, and both symptomatic and asymptomatic infections can induce ISG expression in the upper

respiratory tract mucosa(Landry and Foxman, 2018; Wolsk et al., 2016; Yu et al., 2019). Therefore,

rhinovirus is an example of a common environmental factor which could potentially alter the kinetics of

ISG expression at the initial target site of SARS-CoV-2 infection, the airway epithelium.

Here, we studied the initial host response to SARS-CoV-2 infection and its relationship to viral

replication, including modulation by rhinovirus infection. Due to SARS-CoV-2 screening and testing

practices at our hospital at the start of the pandemic in March 2020, we were able to obtain

nasopharyngeal swab samples from patients at different time points post-infection, including serial

samples collected close to the start of infection in asymptomatic subjects. Using transcriptomic and

biomarker-based analysis of these samples, we observed robust ISG induction in the airway mucosa in

response to SARS-CoV-2, but a delay between viral replication and ISG induction. Using an organoid

infection model, we modulated the kinetics of ISG induction. We found that enhancing ISG expression

by prior exposure to a rhinovirus profoundly inhibited SARS-CoV-2 replication. Blocking ISG induction

completely rescued the effects of interference by rhinovirus, and increased replication rate of SARS-

CoV-2 in a low MOI infection. These results show the importance of interferon-mediated defenses in

restricting SARS-CoV-2 replication at the start of infection and provide an example of how ISG

induction by a different virus could impact susceptibility to SARS-CoV-2 infection.

Results

Nasopharyngeal host response to SARS-CoV-2 infection identified by RNA-Seq

The host response to SARS-CoV-2 in the upper respiratory tract and its relationship to viral replication

are not well-defined. To characterize host responses during SARS-CoV-2 infection in vivo,

we performed RNA-Seq on nasopharyngeal (NP) swab RNA from SARS-CoV-2-positive patients (n=30)

and SARS-CoV-2-negative healthcare worker controls (n=8). Patients included outpatients and patients

admitted to the hospital of both sexes, who ranged in age from 20s to 90s, with the majority above 60

years of age (Fig S1A-D). Samples varied in viral load over >5 orders of magnitude as assessed by RT-

qPCR for the SARS-CoV-2 N1 gene or by read mapping of NP RNA to the SARS-CoV-2 genome, with a

strong correlation seen between PCR Ct value for the SARS-CoV-2 N1 gene and viral RNA reads by

RNA-Seq (r^2=0.8380, p<0.0001; Fig S1E).

Of reads mapping to the human genome, 1770 RNAs differed significantly between SARS-CoV-2+

patients and control subjects (Fig 1A). These included 1567 protein-coding genes, of which 1245 (79.4%)

were enriched and 322 reduced in patients relative to controls. The most significantly enriched genes in

the nasopharynx of SARS-CoV-2 patients were known interferon stimulated genes (ISGs), including three

NP ISG transcripts previously shown by our group to accurately identify patients with viral respiratory

infection, OASL, IFIT2, and CXCL10 (Fig 1A)(Landry and Foxman, 2018). Analysis of ingenuity pathways

and transcription factor binding sites associated with enriched transcripts demonstrated activation of

multiple pathways related to ISG induction in SARS-CoV-2 patients compared to controls, as well as

other pathways linked to innate immunity, leukocyte recruitment, and initiation of mucosal inflammatory

responses (Fig 1B-D).

Examination of gene expression across patient samples revealed several patterns (Fig 1E-G). First, the

45 most significantly enriched genes were all interferon stimulated genes, according to the Interferome

database (Rusinova et al., 2013). ISGs appeared to be co-regulated within individual patients, i.e.

patients with high expression of one ISG tended to have high expression of other ISGs (Fig 1E). This

was also demonstrated by analysis of the correlation between reads for different ISGs across samples

(Fig 1F). Second, ISG expression appeared to be loosely correlated with viral load, with those patients

with the highest viral load (Fig 1E, left) tending to have higher ISG expression than those with the lowest

viral loads (Fig 1E, right). However, while all SARS-CoV-2+ samples showed enrichment of ISG

expression compared to controls, direct comparison of DEGs in patient groups with distinct clinical

characteristics (sex, age, or outpatient/admitted status) showed no significant differences in ISG

expression.

Next, we measured the level of CXCL10 protein in the NP-swab associated viral transport medium using

ELISA. We previously showed that NP CXCL10 is detected in the viral transport medium during other

acute viral respiratory infections and correlates with expression of ISGs at the mRNA level (Landry and

Foxman, 2018). Consistently, we observed a significant positive correlation between NP CXCL10 protein

level with the NP mRNA level of Cxcl10 in SARS-CoV-2+ patient NP samples (Fig 1E, G). Together,

these results indicated that across subjects with diverse clinical presentations, SARS-CoV-2 induced a

robust interferon response in the nasopharynx and that the NP CXCL10 protein level correlated with ISG

expression at the RNA level.

Relationship between SARS-CoV-2 viral load and NP host response in vivo

Next, we sought to examine the host response during SARS-CoV-2 infection in a larger set of samples

from patients evaluated in our healthcare system in March and April of 2020 (n=140) (Fig 2 and Fig S2A,

B), to gain further insight into the relationship between viral replication, disease status, and host response

to infection. Based on our previous studies and our finding that NP CXCL10 protein level correlated with

ISG expression in SARS-CoV-2 positive samples (Fig 1), we used NP CXCL10 as an indicator of the

nasopharyngeal antiviral response. First, we examined NP CXCL10 level in SARS-CoV-2+ individuals

who were tested as outpatients and not admitted to the hospital, compared to those who were admitted.

Notably, we observed significantly higher NP CXCL10 levels in outpatients compared to admitted patients

(Fig 2A, p=0.0019). To understand the reason for this, we first examined patient age, since as a group,

admitted patients were significantly older than outpatients (16 years older on average, Fig S2C).

However, there was no correlation between age and CXCL10 level (Fig S2D). Next, we examined viral

load. We were initially surprised to find that admitted patients had significantly lower viral loads than

outpatients (Fig 2B). This suggested that the main factor driving CXCL10 level was viral load. Supporting

this idea, correlation analysis showed a significant positive correlation between NP CXCL10 level and

viral load by RT-qPCR (for all patients, r^2=0.2030, p<0.0001, Fig 2C). This correlation was also seen in

separate analyses of outpatients and admitted patients, with but no significant difference in the slope of

the CXCL10 vs viral load correlation between these groups, although there was a trend towards a higher

slope in outpatients (Fig 2C). We also observed no significant relationship between sex and NP CXCL10

or sex and viral load in this sample set (Fig S2 E,F).

Prior work on SARS-CoV-2 has shown that the nasopharyngeal viral load is highest in the first few days

of infection, and that the more severe symptoms of COVID-19 requiring hospitalization occur in the

second or third week of infection(Cevik, 2020). Therefore, we hypothesized that admitted patients may

have shown lower viral loads at the time of testing than outpatients because they presented later in

infection, after peak viral replication in the nasopharynx. Consistently, outpatients tended to report fewer

days of symptoms prior to testing compared to admitted patients, although this information was only

available for a subset of patients (about one-third, n=44; Fig 2D).

Viral load and nasopharyngeal CXCL10 patterns in vivo over time

To further evaluate the relationship between viral replication and the innate antiviral response in the

nasopharynx, we examined viral load and NP CXCL10 data in longitudinal samples. First, we examined

viral load from 29 inpatients from March 12 and April 30, 2020 for whom we had at ≥8 sequential tests

results for SARS-CoV-2 with at least the first sample tested using the CDC assay (our clinical laboratory

also had other testing platforms) (Fig 3, Table S1). At this time, most serial testing was aimed at patient

clearance for discharge. Consistently, the majority of patients (15/29) showed low viral loads (Ct N1>21)

which remained low throughout the time course. Another common pattern was high viral load in the first

sample (Ct N1<20) followed by a decline in viral load over time, similar to patterns reported in the literature

for patients who presented close to the start of symptomatic illness (7/29 patients, Fig 3A). These patients

showed high CXCL10 level in the sample with peak viral load and a decline in NP CXCL10 after the viral

load had decreased (Fig 3B). One patient had a consistently high NP viral loads for 20 days and did not

survive (not shown). Finally, a third pattern was seen in a several patients (6/29), in which the first sample

had a low viral load which subsequently increased to a high peak level (Ct N1<20), then decreased over

time (Fig 3). This pattern is consistent with patient presentation close to the start of infection. Two of

these patients had no symptoms of SARS-CoV-2 and the virus was detected incidentally on screening

during hospitalization for other reasons (Fig 3C,D, Table S1). One of these patients had an inconclusive

test and a positive test on the same day, 12 hours later (first test, N1 not detected, N2 Ct 38.4, second

test N1 Ct 34.6, N2 Ct 35.4), suggesting that this might have been the first day of infection for this patient

(L2, Fig 3C). The other four patients presented with acute symptoms including fever, and in some cases

cough and/or shortness of breath. NP CXCL10 in these patients was undetectable or low in the first

positive sample with low viral load, then rose with viral RNA, and then subsequently declined as viral load

declined. Together, the longitudinal data show a correlation with NP CXCL10 and viral load in individual

patients over time, similar to what we observed across 140 patients tested at a single time point (Fig. 2).

Notably, for patient L2, the only patient for whom three samples were available prior to peak viral load,

there appeared to be a delay between CXCL10 production relative to viral replication during the first few

days of infection, suggesting that initially viral replication outpaced the host innate immune response in

the nasopharynx.

SARS-CoV-2 replication kinetics and ISG response early in infection

To further evaluate the kinetics of SARS-CoV-2 replication and host response, we performed a time

course of SARS-CoV-2 infection using primary human airway epithelial cells grown at air-liquid interface,

which differentiate into organoids with beating cilia and mucus production, recapitulating the airway

mucosal surface in vivo. Cultures were inoculated with SARS-CoV-2 on the apical surface, washed after

1 hr, then incubated at 35°C to simulate the temperature of the upper respiratory tract and conducting

airways. Cultures were collected for RNA isolation and RT-qPCR at 1 hr (post-inoculation time point),

24hr, 48hr, 72hr, and 96hr and basolateral media was collected for CXCL10 ELISA. Reminiscent of what

we observed during SARS-CoV-2 infection in vivo (Fig 3D-I), viral load increased rapidly for the first three

days of infection, then plateaued between 72-96 hr (Fig 4A). ISGs were also induced, with ISG mRNA

levels and CXCL10 protein level in the basolateral medium increasing markedly from 72 to 96 hr (Fig 4B-

F). Notably, a very high level of CXCL10 protein was produced by infected epithelia (~4ng/ml by 96 hr),

consistent with the strong NP CXCL10 signal observed in the nasopharynx in vivo.

Doubling time of SARS-CoV-2 in vitro and in vivo

Viral replication in organoid cultures appeared to follow an exponential curve for the first 72hr of infection. Therefore, we used curve-fitting to exponential growth to estimate the doubling time, which was 5.858 hr (95% C.I. of 4.85-7.357 hr., based on 20 y-values, 5 per time point; Fig 4G). For patient L2, viral load data from first three SARS-CoV-2+ time points also appeared to follow exponential growth, therefore we used the same method to estimate the SARS-CoV-2 doubling time in vivo from this data, which was 6.454 hr (95% C.I. 4.261-13.30 hr based on 3 y-values, Fig 4H). For all other patients from whom viral load increased in serial samples (Fig 3), we had only one sample prior to peak viral load. We asked what the doubling times for SARS-CoV-2 would be in these samples if we assumed exponential replication between the first and peak viral RNA values. The calculated doubling times across patients ranged from 3.048-6.509 hr for samples less than or equal to 5 days apart. For the two patients with a larger sampling interval (L44, L12), calculated doubling times were 9.455 and 12.58 hr, although these calculations would be expected to overestimate doubling time if the second sample was taken after viral replication had plateaued or begun to decline. Together, the in vitro and in vivo results indicate that SARS-CoV-2 replicates exponentially during the first few days post-infection prior to the peak host anti-viral response, with an average doubling time of approximately 6 hr.

Effect of prior rhinovirus infection on ISG induction and SARS-CoV-2 replication

One of the many physiological exposures that could potentially alter the local innate immune response to SARS-CoV-2 in the upper airway mucosa is recent infection by other viruses. To model this situation, we used organoid culture to examine the effects of prior exposure to rhinovirus, the most frequently detected virus in the human upper respiratory tract, on subsequent SARS-CoV-2 infection (Fig 5A). Based on previous studies, we expected that rhinovirus might curtail infection by inducing an epithelial antiviral response, but also could potentially promote infection by increasing expression of SARS-CoV-2 entry receptors (Wu et al., 2020; Ziegler et al., 2020). Similar to previous observations, rhinovirus infection (HRV-01A, MOI ~0.05) led to robust induction of interferon stimulated genes by day 3 post-infection (Fig

5B). We then evaluated whether rhinovirus infection altered the expression of ACE2, the SARS-CoV-2

entry receptor. ACE2 was originally reported to be an ISG, but a subsequent study reported that full-

length ACE2, which functions as an entry receptor, is not an ISG, and that a truncated form, dACE2, is

an ISG but is not a functional SARS-CoV-2 entry receptor (Onabajo et al., 2020; Ziegler et al., 2020).

Consistent with this finding, we observed that dACE-2 was significantly induced by rhinovirus infection

(~14-fold) and that, as expected for an ISG, induction was prevented by blocking activation of IRF3, a

transcription factor downstream of viral RNA sensors, using the inhibitor BX795 (Clark et al., 2009). In

contrast, full-length ACE2 expression was slightly but significantly increased by rhinovirus infection(~2-

fold) and this change was not abrogated by BX795, suggesting a different mechanism of induction (Fig

S3.) Rhinovirus infection had no effect on expression of TMPRSS2 (not shown).

Next, we evaluated SARS-CoV-2 replication and ISG induction following infection of airway epithelial

organoids, with or without prior rhinovirus infection. SARS-CoV-2 viral load increased exponentially in

infected cultures without prior RV infection, as observed previously (Fig 4), but showed essentially no

increase when cultures had been exposed to rhinovirus 3 days prior (Fig 5C). Evaluation of ISG

expression over the course of infection showed that at early time points of SARS-CoV-2 infection (24, 48

hr, and sometimes 72hr), ISGs were significantly more highly expressed in RV-preinfected cultures that

in cultures infected with SARS-CoV-2 without prior RV exposure (Fig 5D). This included several ISGs

which have been previously reported to limit coronavirus replication or for which polymorphisms are

linked to disease severity of SARS-CoV or SARS-CoV-2, including ISG15, BST2 (tetherin), and LY6E,

and OAS1-3 (Hamano et al., 2005; He et al., 2006; Ma et al., 2014; Martin-Sancho et al., 2020; Pairo-

Castineira et al., 2020; Pfaender et al., 2020; Taylor et al., 2015) (Fig 5D). Non-linear regression analysis

was consistent with exponential replication of SARS-CoV-2 from 24-72 hr post infection in mock-

pretreated cultures, in contrast to rhinovirus pre-infected cultures which supported essentially no

replication (Fig 5E).

To better understand the timing and breadth of the epithelial host response to rhinovirus that appeared

to limit SARS-CoV-2 replication, we evaluated ISG expression over time for five days post rhinovirus

infection and examined ISG expression and viral infection at the single cell level. Time course analysis

showed that following inoculation, rhinovirus replicated robustly, peaking at 24 hr post-infection, and then

declined significantly but was still detectable by RT-qPCR at day 5, a time point corresponding to 48 hr

post SARS-CoV-2 infection in the sequential infection experiment (FigS4A). ISG expression increased

and decreased in parallel with viral replication but was still significantly higher than in mock-treated cells

at day 5 post-rhinovirus infection(Fig S4B-E). Next, we performed single cell RNA sequencing to evaluate

the host ISG response in infected and bystander cells on day 5 post rhinovirus infection. At this time

point, rhinovirus viral RNA reads were detected in only 70 out of 4200 cells sequenced (Fig 5F). The

infected cells were predominantly ciliated cells but included all major cell types, consistent with the HRV-

01A entry receptor LDL-R being ubiquitously highly expressed throughout the culture (Fig S4F,G).

Although rhinovirus was only detected in a small subset of cells in infected cultures at day 5 (1.67%),

ISGs were elevated in all cells compared to mock-treated cultures (Fig 5F), demonstrating that rhinovirus

infection induces a robust bystander antiviral response in uninfected cells that lasts at least 5 days.

Blocking ISG induction restores SARS-CoV-2 replication following rhinovirus infection

Next, to test whether suppression of SARS-CoV-2 replication by rhinovirus was dependent upon the host

cell interferon response, we pre-treated cells with the signaling inhibitor BX795 18hr before rhinovirus

infection, which prevents interferon and ISG induction by rhinovirus(Fig 6A, B)(Clark et al., 2009; Wu et

al., 2020). There was no significant difference in SARS-CoV-2 viral load in RNA isolated from organoid

cultures at 72 hr for cultures with and without drug treatment, (Fig 6B). The effect of BX795 treatment

was much more striking in the setting of sequential rhinovirus-SARS-CoV-2 infection. As seen previously

(Fig 5), prior infection with rhinovirus suppressed SARS-CoV-2 replication by >1000-fold, but replication

was restored by BX795 pre-treatment (Fig 6C). These results indicate that IRF3 signaling is critical for

the inhibition of SARS-CoV-2 replication by prior rhinovirus infection, consistent with the effects of RV

pre-infection on ISG induction (Fig 5).

RV viral RNA was detected at much lower levels than SARS-CoV2 RNA at this time point (72hr post

SARS-CoV-2 infection, 6 days post-RV infection), and showed a slight reduction during SARS-CoV-2

coinfection without BX-795, but significantly higher levels during co-infection in the presence of BX-795.

This result indicates that the antiviral response limits rhinovirus replication in the setting of SARS-CoV-2

co-infection at this time point, and that both viruses achieve higher viral loads with inhibition of innate

antiviral signaling. In other words, in the presence of an intact antiviral response, viral load of both viruses

is reduced by co-infection, but if the host response is inhibited, the viral load of both viruses is higher

during co-infection. This experiment models viral co-infection in a host with an intact interferon response

(both viruses decrease during co-infection), compared to a host with a deficient interferon response

(equal or greater replication of both viruses during co-infection.)

Blocking ISG induction enhances SARS-CoV-2 replication in a low MOI infection

Next, we further probed the effect of BX-795 treatment on SARS-CoV-2 replication using a ten-fold lower

MOI (MOI ~0.05), conditions under which SARS-CoV-2 would potentially be more sensitive to

suppression by ISGs. Under these conditions, BX795 treatment led to a ~10-fold increase in intracellular

viral load and ~300-fold increase in virus shedding into the apical wash at 72 hr post infection. A trend

towards an increase (5-10x) was also seen at 96 hrs post-infection, although due to variability among

replicates this difference was not statistically significant (Fig 7A, B). Based on these results, we checked

the effect of BX795 on viral shedding into the apical wash in the MOI 0.5 infection (Fig 6) but in this case

results were similar to those observed in organoid cultures (not shown). Next, based on the increase in

viral RNA from 1hr to 72 hr during the low MOI infection, we estimated the effect of BX795 on the SARS-

CoV-2 doubling time in organoid culture. Assuming exponential growth between 1hr and 72 hr, the SARS-

CoV-2 doubling time without BX795 was 5.127 hr (95%C.I. 3.889 to 7.518 hrs), and with BX795 was

3.578 hr (95%C.I. 3.499 to 3.661). We then examined expression of ISGs that have been shown to limit

coronavirus replication and which have high basal expression in airway epithelial cultures including

IFITM3, ISG15, and BST2 (tetherin), thus could be particularly important for limiting a low MOI infection.

Induction of all of these ISGs was suppressed by BX795 pre-treatment (Fig 7D-F). For BST2 mRNA,

blocking ISG induction with BX795 revealed a decrease in BST2 mRNA below the baseline level during

SARS-CoV-2 infection, suggesting that SARS-CoV-2 may antagonize BST2 expression at the mRNA

level, in addition to other mechanisms whereby SARS-CoV-2 or SARS-CoV have been reported to

antagonize BST2 at the protein level (Martin-Sancho et al., 2020; Taylor et al., 2015). The effects of

BX795 on SARS-CoV-2 during low MOI infection indicate that the epithelial antiviral response induced

by SARS-CoV-2 does limit viral replication, albeit to a lesser extent than interference by rhinovirus.

Taken together, our results show that SARS-CoV-2 undergoes exponential replication at the start of

infection and induces ISG expression in vitro and in vivo, and that conditions which alter the initial ISG

expression level or rate of ISG induction, including prior infection by a different virus, can profoundly

impact SARS-CoV-2 replication.

Discussion

SARS-CoV-2 replication in the nasopharynx is known to peak during the first week of infection, but the biological variables governing the rate and magnitude of viral amplification are not fully understood (Cevik, 2020; He et al., 2020). Nasopharyngeal viral load early in infection correlates with likelihood of transmitting the infection, and robust viral amplification in the respiratory tract is also likely a prerequisite, although certainly not the only factor, for progression of COVID-19 disease. Here we present evidence that during the first few days of SARS-CoV-2 infection, the airway interferon response plays a protective role by curtailing viral replication in its initial target tissue: the airway epithelium. Specifically, our data show that the extent of viral replication is determined by the magnitude and timing of the host interferon response during a critical time window at the start of infection.

The interferon response is a potent mechanism of antiviral innate defense at mucosal surfaces and effectively curtails replication of many viruses, most of which also antagonize this host response to some degree in order to enable viral replication(Garcia-Sastre, 2017; Iwasaki, 2012). Viral recognition by innate immune sensors within infected epithelial cells induces expression of type I and type III interferons and interferon stimulated genes (ISGs), a diverse family of antiviral effectors, both directly, in infected cells, and in neighboring cells through paracrine effects of secreted interferons(Odendall and Kagan, 2015; Schneider et al., 2014). SARS-CoV-2 has been reported to induce interferons and ISGs in the airway mucosa in vivo and in vitro (Mick et al., 2020; Mulay et al., 2020; Ravindra et al., 2020; Zhou et al., 2020). Consistently, we observed robust ISG induction in all patients using RNA-Seq of nasopharyngeal RNA, regardless of disease severity or other biological variables (Fig 1). However, there is also convincing evidence that SARS-CoV-2 antagonizes the interferon response in infected cells through multiple mechanisms(Banerjee et al., 2020; Konno et al., 2020; Martin-Sancho et al., 2020; Xia et al., 2020). Our observations with organoid culture (Fig 4), and in the one patient for whom we had multiple longitudinal samples prior to peak viral load (patient L2, Fig 3A) show exponential viral replication at the start of SARS-CoV-2 infection. ISGs are also induced, but it is unclear when this host response becomes

functionally effective. We found that in the first 72 hours of infection, prior to the peak host response,

blocking ISG induction had no effect in SARS-CoV infection at MOI 0.5 (Fig 6), but did increase viral

replication at ten-fold lower MOI (Fig 7; MOI 0.05). Together, these observations support a model in which

antagonism by SARS-CoV-2 attenuates but does not prevent the interferon response and thereby creates

a time window at the start of infection during which the virus can undergo exponential growth.

Due to the nature of exponential growth, a small change in biological variables affecting either the rate of

viral replication or the rate of development of an effective interferon response could have a profound

impact on viral amplification and peak viral load. For example, based on an average viral doubling time

estimated from our data of ~6 hr, a 24 hour delay in the development of an effective interferon response,

for example due to host deficiency in innate immune signaling, would lead to a 16-fold increase in peak

viral load. Thus, a peak viral load of 1000 infectious particles would become 16,000 infectious particles,

an upper airway viral load much more likely to lead to viral transmission or spread of the infection to the

lower respiratory tract. Likewise, if conditions or viral differences allowed the viral doubling time to

decrease by two hrs, from 6 hr to 4hr, this would lead to 16-fold greater viral amplification by 48 hr, and

64-fold greater amplification by 72hr, for the faster growing strain. The extent to which NP viral load

correlates with disease severity is still unclear, although several studies show an association (Huang et

al., 2020; Liu et al., 2020; Yilmaz et al., 2020; Zheng et al., 2020). However, there is strong evidence that

high NP viral load correlates with viral transmission, an issue that has come into focus recently due to

the emergence of SARS-CoV-2 strains that appear to have enhanced transmission, such as the B.1.1.7

strain emerging in the U.K.(Cevik, 2020; He et al., 2020; Prevention, 2021; Singanayagam et al., 2020)

Our study predicts biological features of the virus that could potentially underlie this greater

transmissibility, such as better antagonism of the host interferon response or faster doubling time, both

of which would be expected to increase NP viral load and therefore increase transmissibility.

Conversely, host factors that enhance interferon-mediated defenses could be impactful in reducing peak

viral load or even preventing infection altogether. One factor that is known to alter ISG expression in the

nasopharynx is recent viral infection. In this study, we focused on rhinovirus, the most frequent cause of

the common cold. Recent epidemiological studies have shown that this virus is much more prevalent in

the upper respiratory tract than previously appreciated (Foxman and Iwasaki, 2011; Jartti et al., 2008).

For example, in a recent year-round study, about one-third (34%) of all nasal samples from young children

(<5 yrs) were rhinovirus-positive, regardless of symptoms (Byington et al., 2015). Rhinoviruses and other

respiratory viruses have also been shown to induce ISGs in the nasopharynx in vivo, in both the presence

and absence of symptoms (Landry and Foxman, 2018; Wolsk et al., 2016; Yahya et al., 2017; Yu et al.,

2019). Thus, rhinovirus fits the characteristics of a common environmental factor that could impact ISG

expression in the respiratory tract.

Our data using sequential infection in an airway epithelial organoid model show that prior rhinovirus

infection blocks replication of SARS-CoV-2 that this protection is dependent upon ISG induction.

Furthermore, using time course studies and single cell analysis of organoid cultures, we found that a

significant bystander interferon response can be detected in cells throughout the epithelium for at least 5

days post-rhinovirus infection, even though viral replication peaks at 24 hr and few infected cells are

detected at this time point (Fig 5, Fig S4). This finding is consistent with recent work from our group and

others showing that the host interferon response triggered by one respiratory virus can block infection by

another (Essaidi-Laziosi et al., 2020; Wu et al., 2020). Viral interference seen during sequential influenza

virus infections was in fact the basis for the original discovery and naming of interferons in 1957, but only

recently has this idea been explored in depth with regards to human respiratory viral infections, triggered

in part by epidemiological data suggesting interference among RNA respiratory viruses(Greer et al.,

2009; Isaacs and Lindenmann, 1957; Karppinen et al., 2016; Nickbakhsh et al., 2019; Schultz-Cherry,

2015). ISG induction by an unrelated virus may be particularly effective against a virus like SARS-CoV-

2, since it would pre-empt many of the mechanisms SARS-CoV-2 has in place to antagonize interferon

and ISG induction in response to its own replication, including specific targeting of ISGs effective in

blocking the coronavirus life cycle such as BST2 (Martin-Sancho et al., 2020; Taylor et al., 2015).

The concept of viral interference based on the host interferon response assumes a host with intact innate

immune defenses, which may not always be the case. In our experimental model, there was a profound

difference in the outcome of rhinovirus-SARS-CoV-2 co-infection in the presence and absence of an

intact host cell interferon response (Fig 6). With an intact host response, viral loads of both viruses

decreased, but when the interferon response was blocked, viral loads of both viruses were equal to or

higher than in single infections (Fig 6.) This result illustrates that the expected outcome of a viral co-

infection is not one-size-fits-all: it is likely to be profoundly dependent upon host innate immune status.

Many host factors ranging from genetic polymorphisms to transient environmental conditions in the

airway (e.g. temperature, humidity) can attenuate interferon responses and promote replication of

respiratory viruses, and would likewise be expected to reduce the interferon-mediated protective effects

of viral co-infection (Asgari et al., 2017; Foxman et al., 2015; Kudo et al., 2019; Lamborn et al., 2017;

Mihaylova et al., 2018; Zhang et al., 2020). Also, interference requires closely spaced virus co-exposures,

which may be less frequent at certain times of the year, or during the use of pandemic mitigation

measures. Low rates of influenza during 2020 in the southern hemisphere indicate that the public health

measures put in place to slow the spread of SARS-CoV-2 also suppressed circulation of other respiratory

viruses, although there is some evidence that rhinoviruses have continued to circulate(Olsen et al., 2020;

Poole et al., 2020). Viral interference may become a more important consideration for understanding

susceptibly to COVID-19 and other viral pathogens as society reopens.

There are several important caveats to our study. First, our data indicate a relatively limited effect of the

SARS-CoV-2-induced interferon response on initial viral replication when it is the only virus present, at

least at high MOI (Fig 6). However, the recruitment of cells of the immune system to the respiratory tract,

as indicated by our RNAseq data (Fig 1), could considerably amplify ISG induction in vivo. Recent work

showing that interferon deficiencies are linked to severe COVID-19 indicates the importance of interferon-

mediated defense against this virus in vivo (Bastard et al., 2020; Pairo-Castineira et al., 2020; Zhang et

al., 2020). Second, in vivo virus-host-virus interactions could be more complicated than those seen in

organoid culture; for example, if a viral infection results in residual lung damage this could exacerbate

rather than protect against a subsequent viral respiratory illness. Studying virus-host-virus interactions in

vivo will be an important future direction of this study. For assessing viral interference, it will be critical

not only to look at co-occurrence or sequential occurrence of viral infections, but also to measure the

antiviral response in vivo. For example, symptomatic upper respiratory tract infections induce greater

ISG responses than asymptomatic, and the latter may not cause significant interference(Yahya et al.,

2017). Such studies will be facilitated by increasing development of nasopharyngeal swab-based

methods to assess the airway host immune response, as presented here and in the recent

literature(Landry and Foxman, 2018; Mick et al., 2020; Wolsk et al., 2016; Yu et al., 2019).

In sum, our results demonstrate an important role for the interferon-mediated defenses in curtailing

SARS-CoV-2 replication at the start of infection and compel further studies of how the changing

conditions present in the upper respiratory tract, including recent infection by other viruses, can modulate

host antiviral defenses and alter SARS-CoV-2 infection and transmission.

Acknowledgements

We would like to thank Craig Wilen and Wilen lab members for valuable help and advice, and for providing SARS-CoV-2 virus stock. We thank Maureen Owen, Robin Garner, Greta Edelman, the entire staff of the Yale New Haven Hospital Clinical Virology laboratory, and Amy Likens for their dedicated assistance. We also thank Bryan Pasqualucci and Christopher Castaldi at the Yale Center for Genomic Analysis. Funding was provided by Fast Grants (Emergent Ventures, Mercatus Institute, George Mason University) to E.F.F., the Yale Department of Laboratory Medicine and COVID-19 Dean's Fund (E.F.F.), the China Scholarship Council-Yale World Scholars Fellowship (B.W.), the Gruber Foundation Fellowship (T.W.), and the NIH (T32AI007019, T.W.).

Author Contributions

Conceptualization E.F.F.; Methodology, N.R.C., T.W., V.T.M., B.W., D.Z., M.L.L., and E.F.F.; Investigation N.R.C., T.W., V.T.M., B.W., and E.F.F.; Formal analysis B.W., D.Z., and G.W.; Resources, M.L.L.; Writing – Original Draft, E.F.F.; Writing – Review & Editing, N.R.C., T.W., V.T.M., B.W.,D.Z., G.W., M.L.L., E.F.F.; Funding Acquisition, E.F.F.

Declaration of Interests

Dr. Foxman is an inventor on a pending patent application WO2019/217296 A1 and Dr. Foxman and Dr. Landry are inventors on pending patent application WO2018/071498 Al. The other authors declare no competing interests.

Methods details

RESOURCE AVAILABILITY

Lead Contact

Further information and requests may be directed to, and will be fulfilled by the lead

contact Ellen F. Foxman, ellen.foxman@yale.edu

Materials availability

This study did not generate new reagents.

Data and Code Availability

Nasopharyngeal transcriptome data and single cell RNA sequencing data will be publicly available in the

GEO database at the time of publication.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Ethics statement

The use of clinical samples and data in this study was approved by the Yale Human Research Protection

Program Institutional Review Board (Protocol ID #200002765). Procedures for testing residual clinical

samples and recording linked patient data, followed by sample and data de-identification, were evaluated

and the requirement for specific patient consent was waived. In vitro experiments used primary human

cells obtained from Lonza Bioscience (Walkersville, Maryland, U.S.A.). Lonza guarantees that all tissue

utilized for human cell products is ethically obtained with donor informed consent in accordance with

processes approved by an Institutional Review Board or comparable independent review body.

Clinical samples

We used viral residual nasopharyngeal (NP) samples remaining after clinical testing for CXCL10

measurements and transcriptome analysis. Swab-associated viral transport medium was stored at -80

°C following clinical testing and thawed just prior to ELISA assay or RNA isolation for RNA-Seq. Clinical

information including age, sex, virology results, and specific features of clinical course including

presenting symptoms, hospital admission and length of stay, was extracted from the electronic medical

record and recorded, after which samples were assigned a study code and de-identified. In the clinical

laboratory, SARS-CoV-2 was detected in most samples using an EUA-approved TaqMan assay detecting

the CDC targets N1, N2, and RNAseP (Prevention, 2020). In some longitudinal samples, SARS-CoV-2

was diagnosed with the commercial Cepheid assay (reference); in this case, RT-qPCR for the CDC N1

gene was repeated using RT-qPCR TaqMan assay for the CDC N1 gene as described previously (Cat

no: 10006600, Integrated DNA Technologies, IA)(Vogels et al., 2020).

Primary human bronchial epithelial cells.

Primary human bronchial epithelial cells from healthy adult donors were obtained commercially (Lonza,

Walkersville, MD, USA) and cultured at air-liquid interface according to manufacturer's instructions using

reduced hydrocortisone (Stem Cell Technologies, Vancouver, Canada). Cells were allowed to

differentiate for four weeks by which time they displayed beating cilia and mucus production.

Viruses

Rhinovirus 1A (HRV-01A; ATCC VR-481) was amplified in H1-HeLa cells (ATCC CRL-1985) and titer

was determined by plaque assay as reported previously (Foxman et al., 2015). SARS-CoV-2 (BEI

resources, USA-WA1/2020) was generously provided by the Wilen lab. Virus was cultured on Vero E6

cells and titer was determined by plaque assay as described previously (Ravindra et al., 2020).

RNA isolation from clinical samples

At the time of accessioning, the residual viral transport medium from clinical samples was stored at -80C.

Upon thawing, RNA was isolated from 140µl of transport medium using the Qiagen Viral RNA isolation

kit per manufacturer's instructions (Ref: 52904, Qiagen, Germany) and one aliquot was reserved for

ELISA.

Library preparation and RNA Sequencing

RNA samples were quantified and checked for quality using the Agilent 2100 Bioanalyzer Pico RNA

Assay. Library preparation was performed using Kapa Biosystem's KAPA HyperPrep Kit with RiboErase

(HMR) in which samples were normalized with a total RNA input of 25ng. Libraries were amplified using

15 PCR cycles. Libraries were validated using Agilent TapeStation 4200 D1000 assay and quantified

using the KAPA Library Quantification Kit for Illumina® Platforms kit. Libraries were diluted to 1.3nM and

pooled at 1.25% each of an Illumina NovaSeq 6000 S4 flowcell using the XP workflow to generate 25M

read pairs / sample.

RNA-Seq data analysis

Low quality reads were trimmed and adaptor contamination was removed using Trim Galore (v0.5.0,

https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Trimmed reads were mapped to the

human reference genome (hg38) using HISAT2 (v2.1.0)(Kim et al., 2019). Gene expression levels were

quantified using StringTie (v1.3.3b) with gene models (v27) from the GENCODE project(Pertea et al.,

2015). Differentially expressed genes (adjusted p value < 0.05, fold change cutoff = 2) were identified

using DESeq2 (v 1.22.1) (Love et al., 2014). To avoid the unexpected outlier replacement for sex-linked

genes, we turned off the outlier replacement option in the male vs. female comparison by setting

minReplicatesForReplace=Inf for the DESeq() function in the DESeq2 package.

Visualization of RNA-Seq data. Protein coding genes differentially expressed in SARS-CoV-2+ vs.

negative control were visualized on a volcano plot, with an x-axis cutoff | $\log_2$FC cutoff | =10. All

differentially expressed RNAs are included in Table S1 (n=1770). Significantly differentially expressed

transcripts were defined as those with $\log_2$FC>1 and adjusted p value<0.05. Heatmap shows gene

expression levels of top 45 most significant DEGs using min-to-max scaling of normalized read counts.

Pathway analysis was performed using Ingenuity Pathway Analysis (version 01-16). Transcription factor

motif enrichment analysis was performed using Cytoscape (version 3.8.1) with the iRegulon plug-in

((version 1.3)(Janky et al., 2014).

In vitro infections

We infected primary human bronchial epithelial cells differentiated at air-liquid interface with HRV-01A,

SARS-CoV-2, or both. For SARS-CoV-2, high MOI infection was MOI 0.5 and low MOI infection was MOI

0.05. For HRV-01A, MOI 0.1 was used, as this was the minimum viral inoculum that reproducibly led to

robust HRV-01A viral replication in ALI cultures based on prior studies.

To evaluate the effect of RV on subsequent infection with SARS-CoV-2, we infected with each virus

individually or sequentially and examined the time course of viral amplification and ISG induction. To

formally test whether prior exposure to RV inhibits SARS-CoV-2 replication through activation of the host

cell interferon response, we performed sequential infection studies in the presence of BX795.

RT-qPCR

For RT-qPCR, RNA was isolated from each well of differentiated epithelial cells using the QIAGEN

RNeasy kit by incubating each 24-well insert with 350 μl lysis buffer at room temperature for 5 minutes,

followed by RNA isolation and cDNA synthesis using iScript cDNA synthesis kit (BioRad). To quantify

viral RNA and mRNA levels for interferon stimulated genes and the housekeeping gene HPRT, qPCR

was performed using SYBR green iTaq universal (BioRad) per manufacturer's instructions. Viral RNA

was quantified using primers to the RV genome. Viral RNA per ng total RNA is graphed as fold change

from the limit of detection (40 cycles of PCR) as 2^{40-Ct}. ISG mRNA levels are graphed as fold change from

mock-treated cells or are presented relative to the level of mRNA for the housekeeping gene HRPT (2^{-}

$^{\Delta\Delta CT}$). RT-qPCR for SARS-CoV-2 within cultures was performed using the previously-described TaqMan

assay for the CDC N1 gene with primers and probes provided by IDT (Cat no: 10006600, Integrated DNA

Technologies, IA). RT-qPCR for SARS-CoV-2 in apical was performed using a combined reverse

transcriptase and qPCR reaction using the Luna Universal Probe One-Step RT-qPCR Kit (New England

Biolabs, MA)

The following primers were used for RT-qPCR with SYBR green:

HPRT (F-TGGTCAGGCAGTATAATCCAAAG; R- TTTCAAATCCAACAAAGTCTGGC)

ISG15 (F-CATCTTTGCCAGTACAGGAGC; R-GGGACACCTGGAATTCGTTG)

RSAD2 (F-TCGCTATCTCCTGTGACAGC;R-CACCACCTCCTCAGCTTTTG)

MX1 (F-AGAGAAGGTGAGAAGCTGATCC;R-TTCTTCCAGCTCCTTCTCTCTG)

IFITM3 (F-ATCGTCATCCCAGTGCTGAT;R-ATGGAAGTTGGAGTACGTGG)

IFIT2 (F-CCTCAAAGGGCAAAACGAGG; R-CTGATTTCTGCCTGGTCAGC)

CXCL10 (F-CCTGCAAGCCAATTTTGTCC; R-ATGGCCTTCGATTCTGGATTC

LY6E (F-GCATTGGGAATCTCGTGACA; R-ATGGAAGCCACACCAACATT)

BST2 (F-CACACTGTGATGGCCCTAAT; R-TGTAGTGATCTCTCCCTCAAGC)

IFITM3 (F-ATCGTCATCCCAGTGCTGAT; R-ATGGAAGTTGGAGTACGTGG)

OAS1 (F-GCTCCTACCCTGTGTGTGTGT; R-TGGTGAGAGGACTGAGGAAGA)

OAS3 (F-GAAAACTGTCAAGGGAGGCTC; OAS3 R-CCCTCTGGTCCACATAGCTC)

HRV-01A (F- CAGGCCAAATTAAAGTCAATAAGC; R- AGGCTGAAGTTTGGTTTTGC)

Quantification and statistical analysis, RT-qPCR data

GraphPad Prism (version 9.0.0) was used for data analysis. Data are shown as mean +/- S.E.M.

Statistical significance of differences between conditions was determined by t tests (two-tailed). Linear

regression analysis was used to determine association between clinical parameters, such as viral load

and NP CXCL10 in clinical samples and to test the null hypothesis that the slope of the association was

significantly different from zero. Non-linear regression analysis was used to fit viral growth to an

exponential curve (exponential growth with log(population)) to determine virus doubling times and to test

the null hypothesis that one curve fit both data sets for SARS-CoV-2 growth curve with and without

rhinovirus pre-infection. p<0.05 was considered statistically significant.

ELISA

CXCL10 levels in cell-free residual nasopharyngeal swab samples or tissue culture supernatants was

quantified using a solid phase sandwich enzyme linked immunosorbent assay (ELISA) (Cat no: DY266,

R&D systems, MN). Briefly, frozen viral transport medium from residual nasopharyngeal swab samples

or basolateral medium from organoid cultures was thawed on ice and centrifuged to remove cell debris.

ELISA was performed according to the manufacturer's instructions.

Single cell RNA-Seq of ALI organoid cultures

Library preparation and sequencing

Organoid cultures were digested with trypsin/EDTA to form a single cell suspension. The 10X genomics

Single Cell 3' Protocol was used to produce Illumina-ready sequencing libraries with standard Illumina

paired-end constructs, according to the manufacturer's instructions.

Analysis of scRNA-Seq data

All downstream analyses were implemented using R version 3.6.3 and the package Seurat v3.1.4(Stuart

et al., 2019). The gene expression matrix mock and RV1A infected sample were first individually analyzed

in this procedure: Genes expressed in less than 3 cells and cells expressing less than 200 genes were

discarded. A distribution histogram of UMI count in all cells was made and cells with less than 8000 UMI

counts were discarded. This resulted in a matrix of 21086 genes expressing in 4511 cells in mock sample,

and a matrix of 21195 genes expressing in 4200 cells in RV1A infected sample. The raw counts were

normalized using the Seurat function NormalizeData with normalization.method = "LogNormalize" and

scale.facto = 10000. All genes are scaled using Seurat function ScaleData with default parameters.

Variable features were determined using method "vst". A total of top 2000 variable features were used

for principal component analysis (PCA). Graph based clustering was performed individually on mock and

RV1A infected sample. The KNN graph was built by FindNeighbors function with first 20 principal

components and k.param = 10. Louvain clustering was done using FindCluster function with resolution =

0.8 for both samples. Clusters were separately annotated in the mock and RV1A infected sample using

the following markers of the major cell groups in the airway epithelium: Basal Cycling (MKI67,

HIST1H4C), Basal (KRT14, KRT15, KRT5), Hillock (SPINK5, KRT13), Secretory (SCGB1A1, BPIFA1,

LYPD2), Ciliated (CAPS, PIFO, MORN2), Ionocyte (FOXI1) and PNEC(pulmonary neuroendocrine cells,

markers include AZGP1, AVIL)(Plasschaert et al., 2018). Each cluster found by clustering was assigned

to one of the above seven major groups. A group of developing ciliated cells with marker CCNO was

found in the mock sample and was merged into the ciliated cell cluster. After cluster annotation, mock

and infected samples were merged together to produce tSNE maps and make comparisons. Both

samples used same normalization method and the gene expression level was re-scaled. Dimensionality

reduction was performed by latent semantic analysis using Seurat function RunLSI with the first 50

singular values. The tSNE maps were then produced with the first 50 dimensions and perplexity 30. The

color coding of tSNE plots used cell type, sample source, viral read per cell and expression levels of

genes of interest.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bacterial and Virus Strains		
HRV-01A	ATCC	ATCC VR-481
SARS-CoV-2	BEI resources	USA-WA1/2020
Biological Samples		
Residual nasopharyngeal samples from clinical testing	Yale-New Haven Hospital	
Chemicals, Peptides, and Recombinant Proteins		
BX795	Millipore Sigma	SML0694
Critical Commercial Assays		
iTaq Universal SYBR Green Supermix	BioRad	172-5125
iScript cDNA synthesis kit	BioRad	170-8891BUN
Primer-probe assay for SARS-CoV-2 (N1 gene)	IDT resources	10006600
Luna Universal Probe One-Step RT-qPCR Kit	New England Biolabs	E3006L
QIAamp Viral RNA isolation kit	QIAGEN	52904
QIAGEN RNeasy RNA isolation kit	QIAGEN	74106
Human CXCL10/IP-10 Duoset ELISA kit	R& D systems	DY266
Deposited Data		
Nasopharyngeal transcriptome data – deposited in GEO		
Single cell RNA-Seq data – deposited in GEO		
Experimental Models: Cell Lines		
NHBE-Bronchial Epi Cells for ALI	Lonza Walkersville Inc.	CC-2540S
H1 HeLa cells	ATCC	ATCC CRL-1958
Vero E6 cells	ATCC	ATCC CRL-1586
Oligonucleotides		
Primer sequences provided in Methods details		
Software and Algorithms		
R	www.r-project.org	SCR_001905
Seurat	satijalab.org/seurat/	RRID:SCR_016341
Prism v. 9.0.0 for MacOS	GraphPad	RRID:SCR_005375
Excel v. 16.43	Microsoft	RRID:SCR_016137
Ingenuity Pathway Analysis	QIAGEN	RRID: SCR_008653
Cytoscape	Open source	RRID: SCR_003032

References

Asgari, S., Schlapbach, L.J., Anchisi, S., Hammer, C., Bartha, I., Junier, T., Mottet-Osman, G., Posfay-

Barbe, K.M., Longchamp, D., Stocker, M.*, et al.* (2017). Severe viral respiratory infections in children with

IFIH1 loss-of-function mutations. Proceedings of the National Academy of Sciences of the United States

of America *114*, 8342-8347.

Banerjee, A.K., Blanco, M.R., Bruce, E.A., Honson, D.D., Chen, L.M., Chow, A., Bhat, P., Ollikainen,

N., Quinodoz, S.A., Loney, C.*, et al.* (2020). SARS-CoV-2 Disrupts Splicing, Translation, and Protein

Trafficking to Suppress Host Defenses. Cell.

Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.H., Zhang, Y., Dorgham, K.,

Philippot, Q., Rosain, J., Beziat, V.*, et al.* (2020). Autoantibodies against type I IFNs in patients with life-

threatening COVID-19. Science *370*, eabd4585.

Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.C., Uhl, S., Hoagland, D., Moller, R., Jordan, T.X., Oishi,

K., Panis, M., Sachs, D.*, et al.* (2020). Imbalanced Host Response to SARS-CoV-2 Drives Development

of COVID-19. Cell *181*, 1036-1045 e1039.

Byington, C.L., Ampofo, K., Stockmann, C., Adler, F.R., Herbener, A., Miller, T., Sheng, X., Blaschke,

A.J., Crisp, R., and Pavia, A.T. (2015). Community Surveillance of Respiratory Viruses Among Families

in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE) Study. Clinical

infectious diseases : an official publication of the Infectious Diseases Society of America *61*, 1217-1224.

Cevik, M., Tate, M., Lloyd, O., Maraolo, A.E., Scahfers, J., and A. Ho (2020). SARS-CoV-2, SARS-

CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic

review and meta-analysis. The Lancet Microbe *20*, 30172-30175.

Clark, K., Plater, L., Peggie, M., and Cohen, P. (2009). Use of the pharmacological inhibitor BX795 to

study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream

kinase mediates Ser-172 phosphorylation and activation. J Biol Chem *284*, 14136-14146.

Dong, E., Du, H, L Gardner (2020). An interactive web-based dashboard to track COVID-19 in real

time. ; published online Feb 19.

Essaidi-Laziosi, M., Geiser, J., Huang, S., Constant, S., Kaiser, L., and Tapparel, C. (2020). Interferon-

Dependent and Respiratory Virus-Specific Interference in Dual Infections of Airway Epithelia. Sci Rep

10, 10246.

Feld, J.J., et al (2020). Peginterferon-lambda for the treatment of COVID-19 in outpatients. MedRxiv,

https://doiorg/101101/2020110920228098.

Foxman, E.F., and Iwasaki, A. (2011). Genome-virome interactions: examining the role of common

viral infections in complex disease. Nature reviews Microbiology *9*, 254-264.

Foxman, E.F., Storer, J.A., Fitzgerald, M.E., Wasik, B.R., Hou, L., Zhao, H., Turner, P.E., Pyle, A.M.,

and Iwasaki, A. (2015). Temperature-dependent innate defense against the common cold virus limits

viral replication at warm temperature in mouse airway cells. Proceedings of the National Academy of

Sciences of the United States of America *112*, 827-832.

Galani, I.E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki, E.,

Fragkou, P.C., Panou, V., Rapti, V.*, et al.* (2021). Untuned antiviral immunity in COVID-19 revealed by

temporal type I/III interferon patterns and flu comparison. Nat Immunol *22*, 32-40.

Garcia-Sastre, A. (2017). Ten Strategies of Interferon Evasion by Viruses. Cell Host Microbe *22*, 176-

184.

Greer, R.M., McErlean, P., Arden, K.E., Faux, C.E., Nitsche, A., Lambert, S.B., Nissen, M.D., Sloots,

T.P., and Mackay, I.M. (2009). Do rhinoviruses reduce the probability of viral co-detection during acute

respiratory tract infections? J Clin Virol *45*, 10-15.

Hamano, E., Hijikata, M., Itoyama, S., Quy, T., Phi, N.C., Long, H.T., Ha, L.D., Ban, V.V., Matsushita,

I., Yanai, H.*, et al.* (2005). Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with

SARS in the Vietnamese population. Biochem Biophys Res Commun *329*, 1234-1239.

He, J., Feng, D., de Vlas, S.J., Wang, H., Fontanet, A., Zhang, P., Plancoulaine, S., Tang, F., Zhan,

L., Yang, H., *et al.* (2006). Association of SARS susceptibility with single nucleic acid polymorphisms of

OAS1 and MxA genes: a case-control study. BMC Infect Dis *6*, 106.

He, X., Lau, E.H.Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y.C., Wong, J.Y., Guan, Y., Tan, X., *et*

al. (2020). Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med *26*, 672-675.

Huang, J.T., Ran, R.X., Lv, Z.H., Feng, L.N., Ran, C.Y., Tong, Y.Q., Li, D., Su, H.W., Zhu, C.L., Qiu,

S.L., *et al.* (2020). Chronological Changes of Viral Shedding in Adult Inpatients With COVID-19 in Wuhan,

China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

71, 2158-2166.

Isaacs, A., and Lindenmann, J. (1957). Virus interference. I. The interferon. Proc R Soc Lond B Biol

Sci *147*, 258-267.

Iwasaki, A. (2012). A virological view of innate immune recognition. Annu Rev Microbiol *66*, 177-196.

Janky, R., Verfaillie, A., Imrichova, H., Van de Sande, B., Standaert, L., Christiaens, V., Hulselmans,

G., Herten, K., Naval Sanchez, M., Potier, D., *et al.* (2014). iRegulon: from a gene list to a gene regulatory

network using large motif and track collections. PLoS Comput Biol *10*, e1003731.

Jartti, T., Jartti, L., Peltola, V., Waris, M., and Ruuskanen, O. (2008). Identification of respiratory

viruses in asymptomatic subjects: asymptomatic respiratory viral infections. Pediatr Infect Dis J *27*, 1103-

1107.

Karppinen, S., Toivonen, L., Schuez-Havupalo, L., Waris, M., and Peltola, V. (2016). Interference

between respiratory syncytial virus and rhinovirus in respiratory tract infections in children. Clin Microbiol

Infect *22*, 208 e201-208 e206.

Kim, D., Paggi, J.M., Park, C., Bennett, C., and Salzberg, S.L. (2019). Graph-based genome alignment

and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol *37*, 907-915.

Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R.J., Consortium,

U.-C., Nakagawa, S., *et al.* (2020). SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity

Is Increased by a Naturally Occurring Elongation Variant. Cell Rep *32*, 108185.

Kudo, E., Song, E., Yockey, L.J., Rakib, T., Wong, P.W., Homer, R.J., and Iwasaki, A. (2019). Low

ambient humidity impairs barrier function and innate resistance against influenza infection. Proceedings

of the National Academy of Sciences of the United States of America *116*, 10905-10910.

Lamborn, I.T., Jing, H., Zhang, Y., Drutman, S.B., Abbott, J.K., Munir, S., Bade, S., Murdock, H.M.,

Santos, C.P., Brock, L.G.*, et al.* (2017). Recurrent rhinovirus infections in a child with inherited MDA5

deficiency. J Exp Med *214*, 1949-1972.

Landry, M.L., and Foxman, E.F. (2018). Antiviral Response in the Nasopharynx Identifies Patients

With Respiratory Virus Infection. The Journal of infectious diseases *217*, 897-905.

Lee, J.S., and Shin, E.C. (2020). The type I interferon response in COVID-19: implications for

treatment. Nat Rev Immunol *20*, 585-586.

Liu, Y., Yan, L.M., Wan, L., Xiang, T.X., Le, A., Liu, J.M., Peiris, M., Poon, L.L.M., and Zhang, W.

(2020). Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis *20*, 656-657.

Lokugamage, K.G., Hage, A., de Vries, M., Valero-Jimenez, A.M., Schindewolf, C., Dittmann, M.,

Rajsbaum, R., and Menachery, V.D. (2020). Type I Interferon Susceptibility Distinguishes SARS-CoV-2

from SARS-CoV. J Virol *94*, e01410-01420.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for

RNA-seq data with DESeq2. Genome Biol *15*, 550.

Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson, M.K., Mao, T., Oh,

J.E., Israelow, B.*, et al.* (2020). Longitudinal analyses reveal immunological misfiring in severe COVID-

19. Nature *584*, 463-469.

Ma, X.Z., Bartczak, A., Zhang, J., He, W., Shalev, I., Smil, D., Chen, L., Phillips, J., Feld, J.J., Selzner,

N.*, et al.* (2014). Protein interferon-stimulated gene 15 conjugation delays but does not overcome

coronavirus proliferation in a model of fulminant hepatitis. J Virol *88*, 6195-6204.

Martin-Sancho, L., Lewinski, M.K., Pache, L., Stoneham, C.A., Yin, X., Pratt, D., Churas, C.,

Rosenthal, S.B., Liu, S., De Jesus, P.D.*, et al.* (2020). Functional Landscape of SARS-CoV-2 Cellular

Restriction. bioRxiv.

Mick, E., Kamm, J., Pisco, A.O., Ratnasiri, K., Babik, J.M., Castaneda, G., DeRisi, J.L., Detweiler,

A.M., Hao, S.L., Kangelaris, K.N.*, et al.* (2020). Upper airway gene expression reveals suppressed

immune responses to SARS-CoV-2 compared with other respiratory viruses. Nat Commun *11*, 5854.

Mihaylova, V.T., Kong, Y., Fedorova, O., Sharma, L., Dela Cruz, C.S., Pyle, A.M., Iwasaki, A., and

Foxman, E.F. (2018). Regional Differences in Airway Epithelial Cells Reveal Tradeoff between Defense

against Oxidative Stress and Defense against Rhinovirus. Cell Rep *24*, 3000-3007 e3003.

Monk, P.D., Marsden, R.J., Tear, V.J., Brookes, J., Batten, T.N., Mankowski, M., Gabbay, F.J., ,

Davies, D.E., Holgate, S.T., Ho, L., Clark, T., Djukanovic, R., Wilkinson, T.M.A. (2020). Safety and

efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a

randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine *20*, 30511-

30517.

Mulay, A., Konda, B., Garcia, G., Yao, C., Beil, S., Sen, C., Purkayastha, A., Kolls, J.K., Pociask, D.A.,

Pessina, P.*, et al.* (2020). SARS-CoV-2 infection of primary human lung epithelium for COVID-19

modeling and drug discovery. bioRxiv, https://wwwbiorxivorg/content/101101/20200629174623v1.

Nickbakhsh, S., Mair, C., Matthews, L., Reeve, R., Johnson, P.C.D., Thorburn, F., von Wissmann, B.,

Reynolds, A., McMenamin, J., Gunson, R.N.*, et al.* (2019). Virus-virus interactions impact the population

dynamics of influenza and the common cold. Proceedings of the National Academy of Sciences of the

United States of America.

Odendall, C., and Kagan, J.C. (2015). The unique regulation and functions of type III interferons in

antiviral immunity. Curr Opin Virol *12*, 47-52.

Olsen, S.J., Azziz-Baumgartner, E., Budd, A.P., Brammer, L., Sullivan, S., Pineda, R.F., Cohen, C.,

and Fry, A.M. (2020). Decreased Influenza Activity During the COVID-19 Pandemic - United States,

Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep *69*, 1305-1309.

Onabajo, O.O., Banday, A.R., Stanifer, M.L., Yan, W., Obajemu, A., Santer, D.M., Florez-Vargas, O.,

Piontkivska, H., Vargas, J.M., Ring, T.J.*, et al.* (2020). Interferons and viruses induce a novel truncated

ACE2 isoform and not the full-length SARS-CoV-2 receptor. Nat Genet *52*, 1283-1293.

Pairo-Castineira, E., Clohisey, S., Klaric, L., Bretherick, A.D., Rawlik, K., Pasko, D., Walker, S.,

Parkinson, N., Fourman, M.H., Russell, C.D.*, et al.* (2020). Genetic mechanisms of critical illness in

Covid-19. Nature *https://www.nature.com/articles/s41586-020-03065-y*.

Pertea, M., Pertea, G.M., Antonescu, C.M., Chang, T.C., Mendell, J.T., and Salzberg, S.L. (2015).

StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol *33*,

290-295.

Pfaender, S., Mar, K.B., Michailidis, E., Kratzel, A., Boys, I.N., V'Kovski, P., Fan, W., Kelly, J.N., Hirt,

D., Ebert, N.*, et al.* (2020). LY6E impairs coronavirus fusion and confers immune control of viral disease.

Nat Microbiol *5*, 1330-1339.

Plasschaert, L.W., Zilionis, R., Choo-Wing, R., Savova, V., Knehr, J., Roma, G., Klein, A.M., and Jaffe,

A.B. (2018). A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. Nature

560, 377-381.

Poole, S., Brendish, N.J., Tanner, A.R., and Clark, T.W. (2020). Physical distancing in schools for

SARS-CoV-2 and the resurgence of rhinovirus. Lancet Respir Med *8*, e92-e93.

Prevention, C.f.D.C.a. (2020). CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR

Diagnostic Panel

Prevention, C.f.D.C.a. (2021). Emerging SARS-CoV-2 Variants.

Ravindra, N.G., Alfajaro, M.M., Gasque, V., Wei, J., Filler, R.B., Huston, N.C., Wan, H., Szigeti-Buck,

K., Wang, B., Montgomery, R.R.*, et al.* (2020). Single-cell longitudinal analysis of SARS-CoV-2 infection

in human bronchial epithelial cells. bioRxiv.

Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cumming, H., Chapman, R., and Hertzog,

P.J. (2013). Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic

Acids Res *41*, D1040-1046.

Schneider, W.M., Chevillotte, M.D., and Rice, C.M. (2014). Interferon-stimulated genes: a complex

web of host defenses. Annual review of immunology *32*, 513-545.

Schultz-Cherry, S. (2015). Viral Interference: The Case of Influenza Viruses. The Journal of infectious

diseases *212*, 1690-1691.

Singanayagam, A., Patel, M., Charlett, A., Lopez Bernal, J., Saliba, V., Ellis, J., Ladhani, S., Zambon,

M., and Gopal, R. (2020). Duration of infectiousness and correlation with RT-PCR cycle threshold values

in cases of COVID-19, England, January to May 2020. Euro Surveill *25*.

Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd, Hao, Y., Stoeckius,

M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. Cell *177*, 1888-

1902 e1821.

Taylor, J.K., Coleman, C.M., Postel, S., Sisk, J.M., Bernbaum, J.G., Venkataraman, T., Sundberg,

E.J., and Frieman, M.B. (2015). Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone

Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference. J

Virol *89*, 11820-11833.

Vanderheiden, A., Ralfs, P., Chirkova, T., Upadhyay, A.A., Zimmerman, M.G., Bedoya, S., Aoued, H.,

Tharp, G.M., Pellegrini, K.L., Manfredi, C.*, et al.* (2020). Type I and Type III Interferons Restrict SARS-

CoV-2 Infection of Human Airway Epithelial Cultures. J Virol *94*, e00985-00920.

Vogels, C.B.F., Brito, A.F., Wyllie, A.L., Fauver, J.R., Ott, I.M., Kalinich, C.C., Petrone, M.E.,

Casanovas-Massana, A., Catherine Muenker, M., Moore, A.J.*, et al.* (2020). Analytical sensitivity and

efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nat Microbiol *5*, 1299-1305.

Wang, N., Zhan, Y., Zhu, L., Zheng, Z., Lu, Y., Hong, P. (2020). Retrospective Multicenter Cohort

Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19

Patients. Cell Host Microbe *28*, 455-464.

Wolfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M.A., Niemeyer, D., Jones,

T.C., Vollmar, P., Rothe, C.*, et al.* (2020). Virological assessment of hospitalized patients with COVID-

2019. Nature *581*, 465-469.

Wolsk, H.M., Folsgaard, N.V., Birch, S., Brix, S., Hansel, T.T., Johnston, S.L., Kebadze, T., Chawes,

B.L., Bonnelykke, K., and Bisgaard, H. (2016). Picornavirus-Induced Airway Mucosa Immune Profile in

Asymptomatic Neonates. The Journal of infectious diseases *213*, 1262-1270.

Wu, A., Mihaylova, V.T., Landry, M.L., and Foxman, E.F. (2020). Interference between rhinovirus and

influenza A virus: a clinical data analysis and experimental infection study. Lancet Microbe *1*, e254-e262.

Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J.Y., Wang, H., Menachery, V.D., Rajsbaum, R., and Shi,

P.Y. (2020). Evasion of Type I Interferon by SARS-CoV-2. Cell Rep *33*, 108234.

Yahya, M., Rulli, M., Toivonen, L., Waris, M., and Peltola, V. (2017). Detection of Host Response to

Viral Respiratory Infection by Measurement of Messenger RNA for MxA, TRIM21, and Viperin in Nasal

Swabs. The Journal of infectious diseases *216*, 1099-1103.

Yilmaz, A., Marklund, E., Andersson, M., Nilsson, S., Andersson, L.M., Lindh, M., and Gisslen, M.

(2020). Upper respiratory tract levels of SARS-CoV-2 RNA and duration of viral RNA shedding do not

differ between patients with mild and severe/critical COVID-19. The Journal of infectious diseases *223*,

15-18.

Yu, J., Peterson, D.R., Baran, A.M., Bhattacharya, S., Wylie, T.N., Falsey, A.R., Mariani, T.J., and

Storch, G.A. (2019). Host Gene Expression in Nose and Blood for the Diagnosis of Viral Respiratory

Infection. The Journal of infectious diseases *219*, 1151-1161.

Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I.K.D.,

Hodeib, S., Korol, C.*, et al.* (2020). Inborn errors of type I IFN immunity in patients with life-threatening

COVID-19. Science *370*, eabd4570.

Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., Xie, G., Lin, S., Wang, R., Yang, X.*, et al.* (2020).

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province,

China, January-March 2020: retrospective cohort study. BMJ *369*, m1443.

Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S.*, et al.*

(2020). Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host

Microbe *27*, 883-890 e882.

Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbano, I.M., Miao, V.N., Tzouanas, C.N., Cao, Y., Yousif,

A.S., Bals, J., Hauser, B.M.*, et al.* (2020). SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene

in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell *181*, 1016-

1035 e1019.

Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J.*, et al.*

(2020). SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med *382*,

1177-1179.

Figures

Fig 1. Transcriptome analysis of RNA isolated from SARS-CoV-2+ nasopharyngeal swabs

Fig 2. Relationship between nasopharyngeal (NP) CXCL10 and viral load in 140 SARS-CoV-2+ patients.

Fig 3. Viral load and nasopharyngeal CXCL10 patterns in vivo over time

Fig 4. Kinetics of SARS-CoV-2 replication in organoids and in vivo.

Fig 5. Effect of prior rhinovirus infection on ISG induction and SARS-CoV-2 replication in human airway epithelial organoids.

Fig 6. Effect of blocking ISG induction on SARS-CoV-2 replication following rhinovirus infection.

Fig 7. Effect of blocking ISG induction on SARS-CoV-2 replication in a low MOI infection

Fig 1. Transcriptome analysis of RNA isolated from SARS-CoV-2+ nasopharyngeal swabs.

Fig 1. Transcriptome analysis of RNA isolated from SARS-CoV-2+ nasopharyngeal swabs (related to Fig S1).

(A) Volcano plot showing significantly differentially expressed protein-coding genes based on RNASeq of NP swab RNA from SARS-CoV-2 patients (n=30) compared to control SARS-CoV-2 negative subjects (n=8). Transcripts with fold change>2, adjusted p-value<0.05 are highlighted in red.

(B) Top 20 ingenuity pathways enriched in SARS-CoV-2+ compared to controls, based on 1770 differentially expressed RNAs. P-value and Z-score for each pathway is indicated on the x-axis. Pathways related to interferon and interferon regulatory factor (IRF) signaling are highlighted in red.

(C) Transcription factor binding sites associated with NP transcripts enriched in SARS-CoV-2+ patients compared to controls. Bars show strength of association of motifs/tracks with enriched transcripts, indicated by NES score. Y-axis label indicates top transcription factor associated with each cluster of motifs (M) or tracks (T) and the cluster code. Number of enriched transcripts associated with each track/motif is indicated to the right of each bar. Transcription factors associated with the interferon response are highlighted in red.

(D) Graphical summary of pathways and regulators enriched based on ingenuity pathway analysis of differentially expressed genes enriched in NP RNA of SARS-CoV-2+ patients compared to controls.

(E) Heatmap showing relative expression level of top 45 most significant differentially expressed genes in patients (left) or SARS-CoV-2-negative controls (right). Clinical characteristics of each patient are indicated by color: viral load (red=highest viral load/lowest Ct value, green=lowest viral load/highest Ct value); NP CXCL10 protein level (red=highest, green=lowest, white=data not available). Heatmap colors represent values from highest (red) to lowest (green) for viral load (based on Ct value), CXCL10 concentration (pg/ml), or gene expression level, scaled from minimum to maximum (green=0; yellow=0.5, red=1) Patient characteristics indicated at the top of the graph include Admission status (grey=outpatient, black= admitted); Gender (blue=male, pink=female); Age (blue<55yrs, purple>60 yrs.) White = data not available.

(F) Correlation between reads mapping to CXCL10 and reads mapping to other ISGs (Ifit2, OasL, Isg15).

(G) Correlation between reads mapping to Cxcl10 and CXCL10 protein measured by ELISA in NP swab-associated viral transport medium.

Fig 2 (related to Fig S2). Relationship between nasopharyngeal (NP) CXCL10 and viral load in 140 SARS-CoV-2+ patients.

(A) NP CXCL10 level in patients testing positive for SARS-CoV-2 by RT-qPCR at Yale-New Haven Hospital in March 2020. Black symbols indicate patients tested as outpatients or in the emergency department and not admitted to the hospital, red symbols indicate patients admitted to the hospital.

(B) Ct value for SARS-CoV-2 N1 gene in outpatients and admitted patients. Number in parenthesis (A, B) indicates number of outpatient (total n=38) and admitted (total n=102) samples for which data was available.

(C) Regression analysis showing relationship between viral load and NP CXCL10 protein for all samples (black solid line, r^2 and p-value indicated) or for only outpatients (dashed black line) or admitted patients (dotted red line).

(D) Days of symptoms reported prior to testing for samples with this information available (number indicated n parentheses).

Fig 3 (related to Table S1). Nasopharyngeal viral load and CXCL10 in patients diagnosed prior to peak viral load.

   (A) Viral load over time in seven longitudinal samples from patients with high viral load in first sample (Ct N1>20).

   (B) Paired viral RNA and NP CXCL10 measurements at the peak viral load and at the end viral load, defined as the first sample with Ct N1>30, for 6 patients shown in (G) (data not available for one sample). CXCL10 level was significantly different in peak and end samples by paired t-test.

   (C) – (H) Viral load and NP CXCL10 level in longitudinal samples from SARS-CoV-2+ patients who presented with a low viral load (Ct N1>28) that increased to a high viral load (Ct N1<20). Viral load is expressed as fold change from the limit of detection for the SARS-CoV-2 N1 gene (black circles) and CXCL10 is expressed as pg/ml in the NP-swab associated viral transport medium (red squares). Samples with low levels of RnaseP, an indicator of sample quality, are shown with open symbols. Patient characteristics are described in Table S5.

Figure 4. Kinetics of SARS-CoV-2 replication in organoids and in vivo.
(A) Time course of SARS-CoV-2 replication in human primary airway epithelial organoids, expressed as fold increase from 1hr (post-inoculation time point).
(B) - (E) ISG mRNA level relative to HPRT mRNA in organoids during SARS-CoV-2 infection.
(F) CXCL10 protein in the basolateral medium during SARS-COV-2 replication. For A-H, symbols show mean and S.E.M. of five biological replicates per condition.
(G) Exponential curve fit for increase in RNA during SARS-CoV-2 during replication in organoids from 1-72 hr and calculated doubling time for exponential growth.
(H) Exponential curve fit for increase in viral RNA during SARS-CoV-2 replication for first three virus-positive samples from patient L2 and calculated doubling time for exponential growth with 95% confidence interval.
(I) Estimated doubling times for increase in viral RNA during SARS-CoV-2 replication in patients with one SARS-CoV-2 positive sample prior to peak viral load, shown in fig 3 B-F. Y-axis shows change in viral RNA and x-axis shows time interval between samples. Doubling time calculation assumes exponential growth between first and peak viral load samples.

Figure 5. Effect of prior rhinovirus infection on ISG induction and SARS-CoV-2 replication in human airway epithelial organoids.

(A) Timing of infection of epithelial organoids with rhinovirus followed by SARS-CoV-2

(B) Expression of interferon stimulated genes in airway epithelial organoids 3 days post-rhinovirus infection, relative to mRNA for the housekeeping gene HPRT

(C) SARS-CoV-2 viral RNA at 24, 48, and 72 hr post-infection, with or without RV pre-infection

(D) Expression of interferon stimulated genes at 24, 48, and 72 hr post SARS-CoV-2 infection, with or without RV pre-infection, expressed as fold change from uninfected cells

(E) Replication of SARS-CoV-2 in mock- vs. rhinovirus-pretreated cultures, fit to exponential growth curve

(F) Single cell sequencing of human airway epithelial cell organoids, mock or 5 days post rhinovirus infection. Red and orange dots indicate 70/4200 cells with detectable viral RNA at this time point in rhinovirus-infected cultures (at least 1 read from viral RNA). TSNE plots show expression of mRNA for ISGs in mock and infected cultures at the same time point.

Figure 6. Effect of pretreatment with BX795 during sequential rhinovirus, SARS-CoV-2 infection

Organoid cultures were pretreated with or without BX795 for 18 hr, then mock-infected or infected with HRV01A, incubated for 3 days, then infected with SARS-CoV-2.

- (A) Effect of BX-795 pre-treatment on ISG induction, 3 days post rhinovirus infection. Bars show fold change in ISG mRNA level in RV infected cultures compared to mock without (left) or with (right) BX-795 pre-treatment. P values indicate significant differences between ISG levels in cultures with or without BX795 pretreatment by t-test.

- (B) SARS-CoV-2 viral RNA level relative to the limit of detection in organoid cultures, 72 hr post SARS-CoV-2 infection, with and without BX-795 and/or RV pre-treatment. P values indicate significant differences in viral RNA levels, n.s. = not significant.

- (C) HRV01A viral RNA level relative to the limit of detection in organoid cultures, 72 hr post SARS-CoV-2 infection, with and without BX-795 and/or RV pre-treatment. This graph also includes cultures infected with RV but not subsequently infected with SARS-CoV-2. P values indicate significant differences in viral RNA levels.

For all graphs, bars show mean and S.E.M. of 4-6 biological replicates per condition.

Fig 7. Effect of BX795 on SARS-CoV-2 replication in low MOI infection

(A) Cultures were pre-treated with 6μM BX-795 or medium only, then inoculated with SARS-CoV-2, MOI 0.05, at t=0 hr. Cultures were collected for RNA isolation and RT-qPCR at t=1, 72, and 96 hr post infection. Apical wash was collected at 72 and 92 hr post-infection.

(B)SARS-CoV-2 viral RNA in RNA isolated from organoid cultures 72 hr and 96 hr post-inoculation, with (hatched bars) or without BX795 (black bars), relative to the limit of detection.

(C)SARS-CoV-2 viral RNA in RNA isolated from the apical wash of cultures collected at 72 hr and 96 hr post-inoculation, with (hatched bars) or without BX795 (black bars), relative to the limit of detection.

(D)-(F) ISG mRNA level in SARS-CoV-2 infected cultures, graphed relative to the mRNA level for the housekeeping gene HPRT ($2^{Ct-Ct\ HPRT}$), at 1, 72, or 96 hr post-inoculation.

(B)-(F) Bars show mean and S.E.M. for 4-6 biological replicates per condition. P-values are shown for significant differences, based on the students t-test.